SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Harisankar Aditya) "

Sökning: WFRF:(Harisankar Aditya)

  • Resultat 1-3 av 3
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Harisankar, Aditya (författare)
  • Identification of novel genes with important functions in glioblastoma multiforme and acute myeloid leukemia
  • 2018
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • Glioblastoma multiforme (GBM) is one of the most common and aggressive brain tumors. The cancer stem cells of GBM (GSCs) are notorious for being invasive as well as resistant to radiation and chemotherapy. The current treatment options for GBM lack specificity and result in severe side effects. Therefore, the need for finding novel and efficient treatments with high specificity in GBM has become paramount. In study I, to assess the role of various cytoskeletal regulators as potential biomarkers for prognosis and treatment design in GBM, we analyzed gene expression through a bioinformatics approach. Using this method, we identified six genes having a potential value as biomarkers. In combination, we performed a small molecule screen using various Food and Drug Administration (FDA) approved oncology drugs and compared the effects of these compounds, on GBM cytoskeleton, to the conventional chemotherapeutic temozolomide (TMZ). Our results show the importance of cytoskeletal regulators in GBM and the need for combinatorial therapies. In study II, to identify novel genes required for the growth of acute myeloid leukemia (AML), we performed a large scale short hairpin RNA (shRNA) screen in AML cells and non-transformed bone marrow (BM) cells. We identified the chromatin remodeler, CHD4, as essential for leukemic growth and validated its role in-vitro and in-vivo using RNA interference and CRISPR-Cas9 approaches. More importantly, we found that CHD4 was not required for the growth of normal hematopoietic cells. The study suggests CHD4 as a novel therapeutic target in childhood AML. To identify genes that are required for the growth of GCSs, in studies III and IV, we performed an unbiased functional shRNA screen. Using this approach, in study III, we identified ubiquitin C-terminal hydrolase-L1 (UCHL1) as being selectively essential for the growth of GSCs. Inhibition of UCHL1 was detrimental to GBM cells, caused cell cycle arrest at G0 phase and induced apoptosis. Small molecule inhibitors of UCHL1 effectively and specifically reduced viability of GBM cells and did not affect viability or function of mature neurons. In study IV, we also developed a new shRNA/CRISPR-Cas9 modular vector system for efficient and multiplex validation of genes. From the screening data, we identified Ariadne RBR E3 Ubiquitin Protein Ligase 1 (ARIH1) and Ariadne RBR E3 Ubiquitin Protein Ligase 2 (ARIH2) to be specifically required for the growth of GBM cells. Inhibition of ARIH1 and ARIH2 effectively reduced cell growth of various GBM cell lines, and loss of ARIH2 specifically induced cell cycle arrest and sensitivity to DNA damage. Our data from studies III and IV suggests UCHL1, ARIH1 and ARIH2 as novel targets for future GBM therapies.
  •  
2.
  • Johard, Helena, et al. (författare)
  • HCN Channel Activity Balances Quiescence and Proliferation in Neural Stem Cells and Is a Selective Target for Neuroprotection During Cancer Treatment
  • 2020
  • Ingår i: Molecular Cancer Research. - 1541-7786 .- 1557-3125. ; 18:10, s. 1522-1533
  • Tidskriftsartikel (refereegranskat)abstract
    • Children suffering from neurologic cancers undergoing chemotherapy and radiotherapy are at high risk of reduced neurocognitive abilities likely via damage to proliferating neural stem cells (NSC). Therefore, strategies to protect NSCs are needed. We argue that induced cell-cycle arrest/quiescence in NSCs during cancer treatment can represent such a strategy. Here, we show that hyperpolarization-activated cyclic nucleotide-gated (HCN) ion channels are dynamically expressed over the cell cycle in NSCs, depolarize the membrane potential, underlie spontaneous calcium oscillations and are required to maintain NSCs in the actively proliferating pool. Hyperpolarizing pharmacologic inhibition of HCN channels during exposure to ionizing radiation protects NSCs cells in neurogenic brain regions of young mice. In contrast, brain tumor-initiating cells, which also express HCN channels, remain proliferative during HCN inhibition.
  •  
3.
  • Kitambi, Satish Srinivas, et al. (författare)
  • Vulnerability of Glioblastoma Cells to Catastrophic Vacuolization and Death Induced by a Small Molecule
  • 2014
  • Ingår i: Cell. - : Elsevier BV. - 0092-8674 .- 1097-4172. ; 157:2, s. 313-328
  • Tidskriftsartikel (refereegranskat)abstract
    • Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer with marginal life expectancy. Based on the assumption that GBM cells gain functions not necessarily involved in the cancerous process, patient-derived glioblastoma cells (GCs) were screened to identify cellular processes amenable for development of targeted treatments. The quinine-derivative NSC13316 reliably and selectively compromised viability. Synthetic chemical expansion reveals delicate structure-activity relationship and analogs with increased potency, termed Vacquinols. Vacquinols stimulate death by membrane ruffling, cell rounding, massive macropinocytic vacuole accumulation, ATP depletion, and cytoplasmic membrane rupture of GCs. The MAP kinase MKK4, identified by a shRNA screen, represents a critical signaling node. Vacquinol-1 displays excellent in vivo pharmacokinetics and brain exposure, attenuates disease progression, and prolongs survival in a GBM animal model. These results identify a vulnerability to massive vacuolization that can be targeted by small molecules and point to the possible exploitation of this process in the design of anticancer therapies.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-3 av 3

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy